As Aurinia Pharmaceuticals Inc. marches ahead with the phase III trial testing what could become the first approved lupus nephritis (LN) therapy, company backers are watching with interest another, lesser known indication where the cyclosporine analogue voclosporin might also work: focal segmental glomerular sclerosis (FSGS), a glomerular disease that can cause nephrotic syndrome. A phase II experiment is slated to start next month. Both conditions involve high amounts of protein in the urine, or proteinuria.